ArticleCureus2026
Active Surveillance and Polymerase Chain Reaction (PCR) Between Two Passive Surveillance Periods Improve Detection and Characterization of Pleural Empyema: A 20-Year Study in Tijuana, Mexico.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pleural empyema (PE) surveillance was conducted at Tijuana General Hospital in Tijuana, Mexico, across three distinct periods: passive surveillance (2000-2005), active clinical surveillance with the incorporation of polymerase chain reaction (PCR)-based diagnostics (2005-2018), and a subsequent return to passive surveillance (2022-2024). The implementation of active surveillance coupled with molecular diagnostics substantially improved the detection of PE cases and the identification of causative pathogens, while also enabling the evaluation of the impact of pneumococcal conjugate vaccines (PCVs), including the 7-valent vaccine (PCV7; 2005-2012) and the 13-valent vaccine (PCV13; 2012-2018). This integrated approach provided a more accurate characterization of the etiologic spectrum of PE in children and adolescents, improved antimicrobial susceptibility profiling to better inform clinical management, and generated robust evidence supporting the high effectiveness of PCV13. Collectively, these findings highlight the value of sustained active surveillance and molecular diagnostics in strengthening evidence-based decision-making related to vaccine effectiveness, safety, and potential future vaccine implementation within national immunization programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.